ExonanoRNA Therapeutics

What ExonanoRNA Therapeutics does

ExonanoRNA Therapeutics is a preclinical-stage, privately held biotechnology company founded in 2019 and headquartered in Columbus, Ohio. The company develops exosome-based RNA therapeutics combined with nanoparticle formulation technology to enable intracellular delivery of RNA-based drugs, with an initial focus on oncology applications. Its primary stated customer segment is oncology therapeutics developers, indicating the platform is positioned as either an internal pipeline asset or a potential delivery-licensing play for other RNA therapy developers.

The core technology stack comprises exosome-based delivery vehicles and organic nanoparticle formulation, targeting the well-documented challenge of efficiently transporting RNA payloads into target cells — a critical bottleneck for RNA therapeutics in oncology. The company describes functional benefits including efficient intracellular RNA delivery, support for personalized medicine approaches, and targeted drug delivery for cancer applications. No specific products, named pipeline candidates, IND-stage assets, or peer-reviewed publications are disclosed in the available data.

The business model is not publicly disclosed. Pricing, go-to-market, revenue mechanics, partnership structure, and capital-raising history are all absent from the input data. The company website was in maintenance mode (72% complete) at the time of data collection, social media links on the site are placeholders, and no management team, investors, board composition, regulatory filings, or partner logos are available in the source material. As a 1-10 employee operation with no disclosed funding rounds or revenue, the company is most likely operating on founder capital, grants, or undisclosed seed funding while it advances preclinical work.

Name

ExonanoRNA Therapeutics

Website

https://exonanorna.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

ExonanoRNA Therapeutics is a preclinical-stage biotech developing exosome-based RNA therapeutics and nanoparticle drug-delivery technology, with an initial focus on oncology therapeutics developers. The privately held company is based in Columbus, Ohio.

Ownership category

akta.pro rank

Product category

RNA Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes) (HLAAADAD)

akta.pro secondary industries

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA), RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

Keywords

• RNA therapeutics
• Cancer nanotechnology
• Exosome drug delivery
• RNA nanoparticle formulation
• Oncology drug delivery

Headquarters

HQ city

Columbus

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel

Core offering

ExonanoRNA Therapeutics develops novel RNA nanotechnology-based therapeutics for cancer treatment, leveraging exosome-based delivery systems and organic nanoparticle formulation platforms. The company's work focuses on enabling efficient intracellular delivery of RNA therapeutics for oncological applications via injectable routes.

Differentiator

Problem solved

Functional benefit

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves2 records

Expansion highlights2 records

Emerging players

• Sirnaomics: Sirnaomics develops RNAi-based therapeutics using both GalNAc-conjugate and nanoparticle (PNP) delivery platforms for oncology and anti-fibrotic indications. Comparable due to its dual focus on novel RNA payload and nanoparticle delivery for cancer — directly overlapping ExonanoRNA's targeted oncology use case.
• Coya Therapeutics: Coya is developing exosome-based therapeutics for neurodegenerative and inflammatory indications, building on academic work showing exosomes can deliver RNA and protein cargo. Comparable as another small emerging player betting on exosome-mediated delivery, a thesis ExonanoRNA shares.
• Versatope Therapeutics: Versatope is an early-stage biotech developing exosome-based therapeutics for infectious disease and oncology. Comparable as a small emerging player validating the exosome-as-delivery-vehicle thesis that ExonanoRNA is also pursuing.
• Arbutus Biopharma: Arbutus is focused on developing lipid nanoparticle (LNP) and conjugate delivery technologies for RNAi and mRNA therapeutics, with a Hepatitis B pipeline. Comparable because it competes on RNA delivery vehicle technology rather than a single payload, similar positioning to ExonanoRNA's delivery-platform thesis.

Broad incumbents

• BioNTech: BioNTech is a major mRNA therapeutics platform with multiple delivery technologies (LNP, polymeric, and others) applied to oncology, infectious disease, and rare disease. Comparable as a broad incumbent whose delivery-platform breadth and oncology focus mirror ExonanoRNA's positioning.
• Moderna: Moderna is the leading mRNA therapeutics platform company, with its own LNP delivery technology applied across vaccines, oncology, and rare disease. Comparable as the broad incumbent setting industry expectations for RNA delivery scalability and clinical translation.
• Alnylam Pharmaceuticals: Alnylam is the commercial leader in RNAi therapeutics, with approved siRNA products and broad GalNAc-conjugate delivery expertise. Relevant as the established incumbent whose delivery-platform economics and clinical benchmarks define the bar ExonanoRNA would need to clear.

Direct peers

• Capricor Therapeutics: Capricor develops exosome-based therapeutics (CAP-1002 and the StealthX exosome delivery platform) for inflammatory, infectious, and rare disease indications. Comparable because it commercializes exosomes as a delivery vehicle for nucleic acid and protein cargo, the same core thesis as ExonanoRNA.
• Evox Therapeutics: Evox is a clinical-stage biotech engineering exosome-based therapeutics for delivery of RNA and protein payloads, including in oncology and rare disease. It is the closest direct comparable to ExonanoRNA's exosome-mediated RNA delivery platform.
• Arcturus Therapeutics: Arcturus develops RNA-based therapeutics including mRNA, siRNA, and DNA payloads with proprietary lipid nanoparticle delivery technology for vaccines, rare diseases, and oncology. Comparable as a small/mid-cap RNA delivery platform company targeting similar intracellular delivery challenges.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights3 records

Customer concentration

• LinkedInlinkedin.com/company/exonanorna

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ExonanoRNA Therapeutics